Replies to post #430096 on NorthWest Biotherapeutics Inc (NWBO)

[CaptainObvious]

This looks great. Bookmarking

[sukus]

Awesome!

[hoffmann6383]

my favorite one so far

[extrooper]

Wow, great posting and well done on the timeline (nothing happening). The blind can not see , even when it is in front of them. Thanks for the reposting .

[pgsd]

Thanks, excellent work again.

[flipper44]

Nice, but I thought you were going to correct January 22, 2022 to reflect the Canadien patent (Canada Application 2632263) is what will be issued then.

(Note: as I said last time, the U.S. patent application number you gave on the same specific invention is currently on appeal)

[jm100]

D Dude. way to bring it very nice job.

[jesster64]

Thank You Dude!! I posted link on some discord sites if you dont mind. I made sure to credit you.

[eagle8]

Great piece of work again TDD.

Thank you !

GLTU

[iclight]

Positive findings were reported more quickly than negative ones (median of 272; 95% CI, 211-318 days vs 407; 95% CI, 298-705 days; log-rank P?<?.001).

So positive results never took longer than 318 days. Are we at 705 days yet?

And this from

8 large pharmaceutical companies

Thanks for the info. Great "research".

[OilPatch]

Thank you... FYI your November 29th link goes to the Dec 21 PR.

[Hansm7777]

Hey Danish Dude,
This is a great piece of work that you put together lining up the chronological events and interweaving the puzzle pieces. I am so looking forward to 1st Quarter 2022 NWBO events and news. Furthermore, I am so very elated for all the suffering patients that will eventually be able to believe and participate in the very positive effects of the DCVax platform of medicine. Thank you for your work.
Hans,

[Flexroy]

Great space to filter out the noise. Added to my bookmarks. cheers

[Chiugray]

DD, Thanks for creating a nice resource for information.

[hyperopia]

Nice timeline Dude. Factually, data lock occurred on October 4, 2020, but was announced on October 5:

Overview
The Company is focused on developing personalized immune therapies for cancer. We have developed a platform technology, DCVax®, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer.

Our lead product, DCVax®-L, is designed to treat solid tumor cancers that can be surgically removed. We recently completed our 331-patient international Phase III trial of DCVax-L for newly diagnosed Glioblastome multiforme (GBM).

As previously reported, the data collection and confirmation process was completed by the independent contract research organization (CRO) who managed the trial and by other independent service firms, and we reached Data Lock for the Phase III trial on October 4, 2020.   As explained in our prior announcements, following Data Lock the independent statisticians conduct analyses of the raw data and Trial results for review by the Company, the Principal Investigator, the Steering Committee of the Trial, the Scientific Advisory Board, and a panel of independent brain cancer experts, in preparation for scientific publication and for public announcement. During this process, any questions or comments from the experts will be addressed as part of the preparation of the results for publication and public reporting.

https://sec.report/Document/0001104659-21-004396/